Recombinant Plasma Protein Therapeutics Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Mar 2019| TMR1434A| Transparency

Report Highlights

Global Recombinant Plasma Protein Therapeutics Market: Overview

This report analyzes the current and future scenario of the global recombinant plasma protein therapeutics market. Rise in focus on the treatment of rare diseases, increase in the number of cases with hemophilia A & hemophilia B, and surge in awareness about diagnosis and treatment of hemophilia and other bleeding disorders are major factors that are anticipated to drive the market during the forecast period. Moreover, increase in the number of healthcare providers prescribing recombinant plasma protein therapies for hemophilia A and rapid adoption of genetic engineering technologies in healthcare for the development of new therapeutics are also estimated to fuel the market during the forecast period.

The global recombinant plasma protein therapeutics market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug class, cell line, indication, and region. A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global recombinant plasma protein therapeutics market.

New product launch and FDA approvals are also important factors that are expected to boost the market across the globe. For instance, in April 2018, Shire received FDA approval for VONVENDI recombinant von Willebrand factor indicated for perioperative management of bleeding in patients with von Willebrand disease (VWD)

Global Recombinant Plasma Protein Therapeutics Market: Key Segments

The global recombinant plasma protein therapeutics market has been segmented based on drug class, cell line, and indication. Based on drug class, the market has been classified into recombinant coagulation factors and human C1 esterase inhibitor. The recombinant coagulation factors sub-segment has been further sub-segmented into recombinant coagulation factor VIII, recombinant coagulation factor IX, recombinant coagulation factor VIIa, and others. The recombinant coagulation factor IX sub-segment is anticipated to expand at a rapid pace during the forecast period, due to an increase in the demand for recombinant coagulation factor IX for the treatment of hemophilia B. In terms of cell line, the market has been categorized into Chinese hamster ovary (CHO) cell line, baby hamster kidney (BHK) cell line, human embryonic kidney (HEK) cell line, and others. Based on indication, the market has been segmented into hemophilia A, hemophilia B, Von Willebrand disease, and others. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Recombinant Plasma Protein Therapeutics Market: Regional Outlook

In terms of region, the global recombinant plasma protein therapeutics market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players operating in the global recombinant plasma protein therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Key players profiled in the market report include CSL Limited, Shire (Takeda Pharmaceutical Company Limited), Octapharma, Novo Nordisk A/S, Bayer AG, Bioverativ Therapeutics, Inc. (Sanofi), Aptevo Therapeutics, Pharming Group NV, and Pfizer Inc.

The global recombinant plasma protein therapeutics market has been segmented as below:

Global Recombinant Plasma Protein Therapeutics Market, by Drug Class
Recombinant Coagulation Factors
Recombinant Coagulation Factor VIII
Recombinant Coagulation Factor IX
Recombinant Coagulation Factor VIIa
Others
Human C1 Esterase Inhibitor
 
Global Recombinant Plasma Protein Therapeutics Market, by Cell Line
Chinese Hamster Ovary (CHO) Cell Line
Baby Hamster Kidney (BHK) Cell Line
Human Embryonic Kidney (HEK) Cell Line
Others
 
Global Recombinant Plasma Protein Therapeutics Market, by Indication
Hemophilia A
Hemophilia B
Von Willebrand Disease
Others
 
Global Recombinant Plasma Protein Therapeutics Market, by Region
North America
U.S.
Canada
Europe
Germany
U.K.
Italy
France
Spain
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand

Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa

  • Table 1 : Global Recombinant Plasma Protein Therapeutics Market, New Product Launch and Regulatory Approvals, 2017?2018
  • Table 2 : Global Recombinant Plasma Protein Therapeutics Market, New Product Launch and Regulatory Approvals, 2015?2017
  • Table 3 : Global Recombinant Plasma Protein Therapeutics Market, New Product Launch and Regulatory Approvals, 2014?2015
  • Table 4 : Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 5 : Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factors, 2016–2026
  • Table 6 : Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Cell Line, 2016–2026
  • Table 7 : Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2016–2026
  • Table 8 : Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016–2026
  • Table 9 : North America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 10 : North America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factors, 2016–2026
  • Table 11 : North America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Cell Line, 2016–2026
  • Table 12 : North America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2016–2026
  • Table 13 : North America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016–2026
  • Table 14 : Europe Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 15 : Europe Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factors, 2016–2026
  • Table 16 : Europe Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Cell Line, 2016–2026
  • Table 17 : Europe Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2016–2026
  • Table 18 : Europe Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 19 : Asia Pacific Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 20 : Asia Pacific Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factors, 2016–2026
  • Table 21 : Asia Pacific Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Cell Line, 2016–2026
  • Table 22 : Asia Pacific Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2016–2026
  • Table 23 : Asia Pacific Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 24 : Latin America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 25 : Latin America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factors, 2016–2026
  • Table 26 : Latin America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Cell Line, 2016–2026
  • Table 27 : Latin America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2016–2026
  • Table 28 : Latin America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 29 : Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 30 : Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factors, 2016–2026
  • Table 31 : Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Cell Line, 2016–2026
  • Table 32 : Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2016–2026
  • Table 33 : Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Figure 1 : Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) and Distribution, by Region, 2017 and 2026
  • Figure 2 : Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn), by Drug Class, 2017
  • Figure 3 : Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
  • Figure 4 : Global Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 5 : Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), by Recombinant Coagulation Factors, 2016–2026
  • Figure 6 : Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), by Human C1 Esterase Inhibitor, 2016–2026
  • Figure 7 : Global Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Drug Class, 2018–2026
  • Figure 8 : Global Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Cell Line, 2017 and 2026
  • Figure 9 : Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Chinese Hamster Ovary (CHO) Cell Line , 2016–2026
  • Figure 10 : Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Baby Hamster Kidney (BHK) Cell Line, 2016–2026
  • Figure 11 : Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Human Embryonic Kidney (HEK) Cell Line, 2016–2026
  • Figure 12 : Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2016–2026
  • Figure 13 : Global Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Cell Line, 2018–2026
  • Figure 14 : Global Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication, 2017 and 2026
  • Figure 15 : Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), by Hemophilia A, 2016–2026
  • Figure 16 : Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), by Hemophilia B, 2016–2026
  • Figure 17 : Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), by Von Willebrand Disease, 2016–2026
  • Figure 18 : Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), by Others, 2016–2026
  • Figure 19 : Global Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Indication, 2018–2026
  • Figure 20 : Global Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Region, 2017 and 2026
  • Figure 21 : Global Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Region, 2018–2026
  • Figure 22 : North America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
  • Figure 23 : North America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 24 : North America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Drug Class, 2018–2026
  • Figure 25 : North America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Cell Line, 2017 and 2026
  • Figure 26 : North America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Cell Line, 2018–2026
  • Figure 27 : North America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication, 2017 and 2026
  • Figure 28 : North America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Indication, 2018–2026
  • Figure 29 : North America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Country, 2017 and 2026
  • Figure 30 : North America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
  • Figure 31 : Europe Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
  • Figure 32 : Europe Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 33 : Europe Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Drug Class, 2018–2026
  • Figure 34 : Europe Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Cell Line, 2017 and 2026
  • Figure 35 : Europe Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Cell Line, 2018–2026
  • Figure 36 : Europe Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication, 2017 and 2026
  • Figure 37 : Europe Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Indication, 2018–2026
  • Figure 38 : Europe Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 39 : Europe Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
  • Figure 40 : Asia Pacific Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
  • Figure 41 : Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 42 : Asia Pacific Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Drug Class, 2018–2026
  • Figure 43 : Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Cell Line, 2017 and 2026
  • Figure 44 : Asia Pacific Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Cell Line, 2018–2026
  • Figure 45 : Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication, 2017 and 2026
  • Figure 46 : Asia Pacific Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Indication, 2018–2026
  • Figure 47 : Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 48 : Asia Pacific Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
  • Figure 49 : Latin America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
  • Figure 50 : Latin America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 51 : Latin America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Drug Class, 2018–2026
  • Figure 52 : Latin America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Cell Line, 2017 and 2026
  • Figure 53 : Latin America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Cell Line, 2018–2026
  • Figure 54 : Latin America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication, 2017 and 2026
  • Figure 55 : Latin America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Indication, 2018–2026
  • Figure 56 : Latin America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 57 : Latin America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
  • Figure 58 : Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
  • Figure 59 : Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 60 : Middle East & Africa Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Drug Class, 2018–2026
  • Figure 61 : Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Cell Line, 2017 and 2026
  • Figure 62 : Middle East & Africa Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Cell Line, 2018–2026
  • Figure 63 : Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication, 2017 and 2026
  • Figure 64 : Middle East & Africa Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Indication, 2018–2026
  • Figure 65 : Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 66 : Middle East & Africa Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
  • Figure 67 : Global Recombinant Plasma Protein Therapeutics Market Share, by Company, 2017
  • Figure 68 : CSL Behring Business Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018
  • Figure 69 : CSL Limited R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018
  • Figure 70 : CSL Limited Breakdown of Net Sales (%), by Region, 2018
  • Figure 71 : CSL Behring Breakdown of Net Sales (%), by Therapeutic Area, 2018
  • Figure 72 : Shire Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 73 : Shire R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 74 : Shire Breakdown of Net Sales (% Share), by Region (2017)
  • Figure 75 : Shire Breakdown of Net Sales (% Share), by Therapeutic Areas (2017)
  • Figure 76 : Octapharma Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 77 : Octapharma Research and Development Expenses, 2015-2017
  • Figure 78 : Novo Nordisk A/S Biopharmaceuticals Business Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2018
  • Figure 79 : Novo Nordisk A/S R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018
  • Figure 80 : Novo Nordisk A/S Breakdown of Net Sales (%), by Region, 2018
  • Figure 81 : Novo Nordisk A/S Biopharmaceuticals Business Segment Breakdown of Net Sales (%), by Therapeutic Area, 2018
  • Figure 82 : Bayer AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2017
  • Figure 83 : Bayer AG Pharmaceutical Business Segment R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 84 : Bayer AG Breakdown of Net Sales (%), by Region, 2017
  • Figure 85 : Bayer AG Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 86 : Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 87 : Pfizer Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 88 : Pfizer Inc. Breakdown of Net Sales (%), by Region, 2017
  • Figure 89 : Pfizer Inc. Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 90 : Bioverativ Therapeutics, Inc. Pharmaceuticals Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 91 : Bioverativ Therapeutics, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2017
  • Figure 92 : Bioverativ Therapeutics, Inc. Breakdown of Net Sales (%), by Country, 2017
  • Figure 93 : Aptevo Therapeutics Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2017
  • Figure 94 : Aptevo Therapeutics IXINITY R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2017
  • Figure 95 : Pharming Group NV Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 96 : Pharming Group NV R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 97 : Pharming Group NV Breakdown of Net Sales (%), by Region, 2017

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us